707 related articles for article (PubMed ID: 17234749)
21. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
[TBL] [Abstract][Full Text] [Related]
22. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy.
Kanai R; Eguchi K; Takahashi M; Goldman S; Okano H; Kawase T; Yazaki T
J Gene Med; 2006 Nov; 8(11):1329-40. PubMed ID: 16955534
[TBL] [Abstract][Full Text] [Related]
23. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
Li H; Dutuor A; Fu X; Zhang X
J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
[TBL] [Abstract][Full Text] [Related]
24. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms.
Miao WM; Seng WL; Duquette M; Lawler P; Laus C; Lawler J
Cancer Res; 2001 Nov; 61(21):7830-9. PubMed ID: 11691800
[TBL] [Abstract][Full Text] [Related]
25. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
Kambara H; Okano H; Chiocca EA; Saeki Y
Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
[TBL] [Abstract][Full Text] [Related]
26. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12.
Wong RJ; Chan MK; Yu Z; Ghossein RA; Ngai I; Adusumilli PS; Stiles BM; Shah JP; Singh B; Fong Y
Clin Cancer Res; 2004 Jul; 10(13):4509-16. PubMed ID: 15240543
[TBL] [Abstract][Full Text] [Related]
27. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus.
Fu X; Tao L; Cai R; Prigge J; Zhang X
Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513
[TBL] [Abstract][Full Text] [Related]
28. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
29. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
[TBL] [Abstract][Full Text] [Related]
30. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
Kuroda T; Rabkin SD; Martuza RL
Cancer Res; 2006 Oct; 66(20):10127-35. PubMed ID: 17047077
[TBL] [Abstract][Full Text] [Related]
31. Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment.
Huszthy PC; Immervoll H; Wang J; Goplen D; Miletic H; Eide GE; Bjerkvig R
Gene Ther; 2010 Feb; 17(2):202-16. PubMed ID: 19829315
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
[TBL] [Abstract][Full Text] [Related]
33. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
[TBL] [Abstract][Full Text] [Related]
34. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.
Lamfers ML; Gianni D; Tung CH; Idema S; Schagen FH; Carette JE; Quax PH; Van Beusechem VW; Vandertop WP; Dirven CM; Chiocca EA; Gerritsen WR
Cancer Res; 2005 Oct; 65(20):9398-405. PubMed ID: 16230403
[TBL] [Abstract][Full Text] [Related]
35. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
36. The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells.
Katsura T; Iwai S; Ota Y; Shimizu H; Ikuta K; Yura Y
Cancer Gene Ther; 2009 Mar; 16(3):237-45. PubMed ID: 18949013
[TBL] [Abstract][Full Text] [Related]
37. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases.
Nomura N; Kasuya H; Watanabe I; Shikano T; Shirota T; Misawa M; Sugimoto H; Kanazumi N; Nomoto S; Takeda S; Nakao A
Cancer Chemother Pharmacol; 2009 Jan; 63(2):321-30. PubMed ID: 18575868
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.
Todo T; Martuza RL; Rabkin SD; Johnson PA
Proc Natl Acad Sci U S A; 2001 May; 98(11):6396-401. PubMed ID: 11353831
[TBL] [Abstract][Full Text] [Related]
39. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.
Rofstad EK; Henriksen K; Galappathi K; Mathiesen B
Cancer Res; 2003 Jul; 63(14):4055-61. PubMed ID: 12874006
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
Chung YS; Miyatake S; Miyamoto A; Miyamoto Y; Dohi T; Tanigawa N
Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]